Grifols S.A. ADR Stock
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Grifols S.A. ADR | 1.720% | 4.425% | -6.349% | -10.606% | -36.216% | -60.135% | -65.698% |
Beximco Pharmaceuticals Ltd. GDR | - | -2.326% | -3.670% | 2.439% | -4.545% | -56.250% | -24.324% |
Cellectar BioSciences Inc. | -1.890% | 6.897% | -10.405% | 121.429% | 35.965% | -75.591% | - |
Arca Biopharma | -7.890% | -8.589% | 4.196% | 66.017% | 91.640% | 15.504% | -94.744% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating.
Show more
Ratings data for GRFS provided by MarketBeat